By Benjamin Chiou
Date: Friday 16 Jan 2026
(Sharecast News) - Berenberg has raised its target price for Genus following the animal genetics group's first-half trading update on Friday, keeping the stock at a 'buy' citing "multiple catalysts" for the year ahead.
| Form 8.3 - Oxford Biomedica plc | 19-Jan-2026 | 11:48 | RNS |
| Form 8.5 (EPT/NON-RI) - Oxford Biomedica plc | 19-Jan-2026 | 10:35 | RNS |
| Form 8.5 (EPT/NON-RI) Oxford Biomedica Plc | 19-Jan-2026 | 10:08 | RNS |
| Rule 2.9 Announcement | 19-Jan-2026 | 07:00 | RNS |
| Directorate change | 19-Jan-2026 | 07:00 | RNS |
| Questor :GW Pharmaceuticals | 04-Dec-2014 | Telegraph |
| Questor : Hikma Pharmaceuticals | 13-Mar-2014 | Telegraph |
| Investment Column:BTG | 06-Oct-2011 | The Independent |
| Investment Column:Genus | 09-Sep-2011 | The Independent |
| Questor :Dechra Pharmaceuticals | 08-Sep-2011 | Telegraph |
| Price | 25,892.46 |
| Closing Price Change | -47.66 |
| % Change | -0.18 % |
| 16-Jan-26 Close | 25,892.46 |
You are here: research